BTBD7
BTBD7 is involved in epithelial cell dynamics and tissue remodeling. Alterations have been explored in cancer biology research and may be relevant in emerging therapeutic or biomarker contexts.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where BTBD7 is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Colorectal Cancer (CRC) Solid Tumor · Colorectal |
|
Approvals defined at the solid tumor level where BTBD7 is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report BTBD7 as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports BTBD7 as part of its biomarker panel.